Sidley Austin represented Ardent Health Partners, Inc. in the offering, and Latham & Walkins represented the underwriters. Ardent Health Partners, Inc. (f/k/a Ardent Health Partners, LLC...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Disc Medicine, Inc. on the offering, and Wilmer Cutler Pickering Hale and Dorr advised the underwriter. Disc Medicine, Inc. (Nasdaq: IRON) (“Disc”) announced...
You must be a Standard 1 Year member to access this content.
O’Melveny & Myers represented Nkarta, Inc. in the offering, and Shearman & Sterling represented the underwriters. Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Leerink Partners and Stifel as joint bookrunning managers in the offering. Evolus, Inc. (Nasdaq: EOLS) announced the pricing of its underwritten offering...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised J.P. Morgan and Leerink Partners as co-lead placement agents, and Stifel co-placement agent, in the transaction. Lexeo Therapeutics, Inc. (Nasdaq: LXEO) has entered...
You must be a Standard 1 Year member to access this content.
White & Case LLP has advised Helix Acquisition Corp. II, while Kirkland & Ellis has advised the underwriter on the transaction. Helix Acquisition Corp. II (Helix...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Tenaya Therapeutics on the transaction, and Davis Polk & Wardwell advised the underwriters. Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Leerink Partners on the matter. PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the...
You must be a Standard 1 Year member to access this content.
Homburger advised Jefferies LLC and Leerink Partners LLC on the deal. AC Immune SA, a Swiss clinical stage biopharmaceutical company pioneering in precision medicine for neurodegenerative...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler advised Celldex Therapeutics, Inc. on the offering, and Wilmer Cutler Pickering Hale and Dorr advised the underwriters. Celldex Therapeutics, Inc. (Nasdaq: CLDX) (“Celldex”) announced the...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Alpine Immune Sciences on the offering, and Latham & Watkins advised the underwriters. Alpine Immune Sciences, Inc. (Nasdaq: ALPN) announced the...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised the underwriters in connection with Lexeo Therapeutics’ IPO. Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to transforming...
You must be a Standard 1 Year member to access this content.
